| Hugo St Hilaire, MD, | |
|
4429 Clara St Ste 330, New Orleans, LA 70115-6957 | |
| (888) 890-3437 | |
| (843) 727-3774 |
| Full Name | Hugo St Hilaire |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 23 Years |
| Location | 4429 Clara St Ste 330, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114121639 | NPI | - | NPPES |
| 1238767 | Medicaid | LA | |
| 08534755 | Medicaid | MS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Clinic Foundation | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Louisiana State University School Of Medicine In New Orleans Faculty G | 0244136448 | 380 |
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
| Entity Name | Louisiana Department Of Health - Office Of Public Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144372343 PECOS PAC ID: 5890700694 Enrollment ID: O20140815000393 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
| Entity Name | Southeastern Reconstructive Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871901009 PECOS PAC ID: 3072900794 Enrollment ID: O20220428000493 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hugo St Hilaire, MD, 2 Tokalon Pl, Metairie, LA 70001-3020 Ph: (504) 287-7704 | Hugo St Hilaire, MD, 4429 Clara St Ste 330, New Orleans, LA 70115-6957 Ph: (888) 890-3437 |
News Archive
A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).
Resistance to antituberculosis drugs has been rising in Botswana since 1995, concludes a Research Letter in this weeks issue of The Lancet. Enhanced interventions for TB control are urgently needed in Botswana to prevent further emergence of drug resistance, state the authors.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.
› Verified 2 days ago
Dr. Danielle Nichole Atwood, MD, PHD Plastic Surgery Medicare: Medicare Enrolled Practice Location: 2400 Canal Street, Attn: Surgery Services 112, New Orleans, LA 70119 Phone: 501-690-9069 | |
Ms. Caroline Michelle Burg, NP Plastic Surgery Medicare: Medicare Enrolled Practice Location: 5620 Read Blvd, New Orleans, LA 70127 Phone: 504-592-6437 | |
Radbeh Torabi, MD Plastic Surgery Medicare: May Accept Medicare Assignments Practice Location: 1542 Tulane Ave, Room 734b, New Orleans, LA 70112 Phone: 401-919-0355 | |
Kristopher Mulraj Katira, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-0663 | |
Dr. John Mark Church Jr., M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3525 Prytania St, Suite 230, New Orleans, LA 70115 Phone: 504-895-4561 Fax: 504-895-8529 | |
Christopher James Goodenough, Plastic Surgery Medicare: Medicare Enrolled Practice Location: 4414 Carondelet St, New Orleans, LA 70115 Phone: 978-996-0969 | |
Dr. Mark Winston Stalder, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6028 Magazine St, New Orleans, LA 70118 Phone: 504-800-8058 Fax: 504-387-6538 |